Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Pharmacometrics: Implications and Impact in Preclinical to Early Phase Clinical Development
Track : Track 04: Nonclinical and Translational Development/Early Phase Clinical Development
Program Code: 332
Date: Wednesday, June 26, 2013
Time: 10:15 AM to 11:45 AM  EST
Location: 105
CHAIR :
 Royce A. Morrison, MD,MS (SCHNON), Executive Vice-Chair, Quorum Review, Inc., United States
SPEAKER (S):
 Dinah Duarte, PharmD,MSc (SPKAGY), Head, Scientific Evaluation Unit, Directorate of Medicinal Products, INFARMED, Portugal
 Jogarao V. Gobburu, PhD,MBA (SPKSUP), Professor, School of Pharmacy and School of Medicine, University of Maryland, United States
 Royce A. Morrison, MD,MS (SPKNON), Executive Vice-Chair, Quorum Review, Inc., United States
Arnab Mukherjee, (SPKNON), Director, Specialty Care Clinical Pharmacology, Pfizer Inc, United States
Description
Increasingly, sponsors' and regulators' decisions in drug programs are being driven by pharmacometric methods. Early phase trials will change to give the right range of data for physiologically- and pharmacologically-based modeling and simulations.

Session Recording
(Code: 332)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON4 Comp Access: Wednesday Online Access Package - June 26, 2013
Handout Online
(Code: 332)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON4 Comp Access: Wednesday Online Access Package - June 26, 2013
Pharmacometrics: Implications and Impact in Preclinical to Early Phase Clinical Development